TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE

1. TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Validation of Analytical Methods Used For Bioequivalence Studies Presented by John Gordon, Ph.D. Consultant to WHO e-mail: john_gordon@hc-sc.gc.ca Kyiv, 2005-10-06

2. Bioanalytical Method Validation Quantitative determinations of drugs in biological samples, such as blood or plasma, play a significant role in evaluation and interpretation of bioequivalence data. Kyiv, 2005-10-06

3. Bioanalytical Method Validation Essential to use a well-characterised and fully validated analytical method to yield reliable results. Kyiv, 2005-10-06

4. Development / Use of a Bioanalytical Method • Reference standard preparation • Method procedure development • Application of validated method to routine analysis Kyiv, 2005-10-06

5. Reference Standards • Calibration standards / Quality control samples • Authenticated reference • Known identity • Known purity • Reference standard should be identical to analyte, if possible Kyiv, 2005-10-06

6. Method Development • Chromatographic assays • e.g., gas chromatography, liquid chromatography • Ligand-binding assays • e.g., radioimmunoassay (RIA) Kyiv, 2005-10-06

7. Bioanalytical Method Validation • Method Validation should include • Accuracy • Precision • Sensitivity • Specificity • Recovery • Stability Kyiv, 2005-10-06

8. Bioanalytical Method Validation Accuracy Closeness of determined value to the true value. The acceptance criteria is mean value  15% deviation from true value. At LOQ, 20% deviation is acceptable. Kyiv, 2005-10-06

9. Bioanalytical Method Validation Precision The closeness of replicate determinations of a sample by an assay. The acceptance criteria is  15% CV. At LOQ, 20% deviation is acceptable. Kyiv, 2005-10-06

10. Bioanalytical Method Validation Sensitivity The limit of quantitation (LOQ) is the lowest concentration which can be measured with acceptable accuracy and precision. Kyiv, 2005-10-06

11. Bioanalytical Method Validation Calibration Curve • Sufficient number of calibration standards must be employed • Typically 6 – 8 non-zero standards • Blank sample • Zero sample • Lower Limit of Quantification (LLOQ) • Goodness of fit statistics Kyiv, 2005-10-06

12. Bioanalytical Method Validation Specificity (selectivity) Ability of the method to measure only what it is intended to measure in the presence of other components in the sample. Blank samples of the biological matrix should be tested for interfering peaks. Kyiv, 2005-10-06

13. Bioanalytical Method Validation Recovery The extraction efficiency of an analytical process, reported as a percentage of the known amount of an analyte carried through the sample extraction and processing steps of the method. Recovery does not have to be 100%, but the extent of recovery of an analyte and of the internal standard should be consistent. Kyiv, 2005-10-06

14. Bioanalytical Method Validation Stability • Stability of the analyte in the biological matrix • Sample collection • Sample storage • Sample analysis Kyiv, 2005-10-06

15. Bioanalytical Method Validation Stability • Freeze-thaw stability • Short-term stability • Long-term stability • Post-preparation stability • Stock solution stability Kyiv, 2005-10-06

16. Bioanalytical Method Validation Dilution integrity • Confirm ability to dilute samples above Upper Limit of Quantitation (ULOQ) • Accuracy and precision Kyiv, 2005-10-06

17. Bioanalytical Method Validation Additional considerations for ligand-binding assays • Cross-reactivity • Matrix effects • Concentration-response relationship Kyiv, 2005-10-06

18. Clinical Sample Analysis • Single determination of calibration standards • Calibration curve for each analytical run • Extrapolation below or above calibration range not acceptable Kyiv, 2005-10-06

19. Clinical Sample Analysis Quality control (QC) • At least three concentrations • Low concentration • Midrange concentration • High concentration • Duplicate determinations • 4 out of 6 QC samples must be  15% of nominal value; two outside cannot be at the same concentration Kyiv, 2005-10-06

20. Clinical Sample Analysis Repeat sample analysis • Clear SOP and acceptance criteria • Reasons for re-analysis • Analytical issues • Problematic pharmacokinetic fit • Explanation for missing samples Kyiv, 2005-10-06

21. Standard Operating Procedures • Complete written set of SOPs • Quality control and assurance • All aspects of analysis should be covered including • Record keeping • Security • Chain of sample custody • Sample preparation • Analytical tools • Procedures for quality control and verification of results Kyiv, 2005-10-06

22. Full / Partial Validation • Full validation • During method development • Partial validation • Transfer between laboratories • Change in instrument / software • Change in anticoagulant • Minor changes in sample processing procedures Kyiv, 2005-10-06

23. Bioanalytical Method Validation Useful references: FDA Guidance for Industry • Bioanalytical Method Validation (May 2001)(http://www.fda.gov/cder/guidance/4252fnl.pdf) Published Workshop Reports • Shah, V.P. et al, Pharmaceutical Research: 1992; 9:588-592 • Shah, V.P. et al, Pharmaceutical Research: 2000; 17: 1551-1557 Kyiv, 2005-10-06